Overview

Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation

Status:
Completed

Trial end date:
2021-03-22

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to characterize the impact of inhaled remdesivir (RDV) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in participants with early stage coronavirus disease 2019 (COVID-19).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Remdesivir